Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Xi Li, Ming Li, Yuan Li, Qiankun Quan, Juan Wan. Cellular and molecular mechanisms underlying the action of ginsenoside Rg1 against Alzheimer's disease. Neural regeneration research. vol 7. issue 36. 2014-10-15. PMID:25317137. |
these results suggest that ginsenoside rg1 upregulates brain-derived neurotrophic factor expression and inhibits tau protein phosphorylation in brain slices from a rat model of alzheimer's disease. |
2014-10-15 |
2023-08-13 |
rat |
John F Castro-Alvarez, S Alejandro Uribe-Arias, Kenneth S Kosik, Gloria P Cardona-Góme. Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. Frontiers in aging neuroscience. vol 6. 2014-10-13. PMID:25309427. |
long- and short-term cdk5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic alzheimer's mice. |
2014-10-13 |
2023-08-13 |
mouse |
Michael Deuschle, Claudia Schilling, F Markus Leweke, Frank Enning, Thomas Pollmächer, Hermann Esselmann, Jens Wiltfang, Lutz Frölich, Isabella Heuse. Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. Neuroscience letters. vol 561. 2014-10-07. PMID:24373987. |
we analyzed aβ40, aβ42, tau protein, phosphorylated tau (ptau) protein as well as hypocretin-1 concentrations in the csf of a detection sample of 10 patients with alzheimer's disease (ad) as well as 10 age- and gender-matched patients with major depression as a comparison group of different pathology. |
2014-10-07 |
2023-08-12 |
Not clear |
Jamie Toombs, Ross W Paterson, Michael P Lunn, Jenifer M Nicholas, Nick C Fox, Miles D Chapman, Jonathan M Schott, Henrik Zetterber. Identification of an important potential confound in CSF AD studies: aliquot volume. Clinical chemistry and laboratory medicine. vol 51. issue 12. 2014-10-06. PMID:23940064. |
cerebrospinal fluid (csf) amyloid β1-42 (aβ1-42), total tau (t-tau) and phosphorylated tau181 (p-tau) are finding increasing utility as biomarkers of alzheimer's disease (ad). |
2014-10-06 |
2023-08-12 |
Not clear |
Eloi Magnin, Claire Paquet, Maité Formaglio, Bernard Croisile, Ludivine Chamard, Carole Miguet-Alfonsi, Gregory Tio, Julien Dumurgier, Isabelle Roullet-Solignac, Mathilde Sauvée, Catherine Thomas-Antérion, Alain Vighetto, Jacques Hugon, Pierre Vande. Increased cerebrospinal fluid tau levels in logopenic variant of Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 39. issue 3. 2014-10-06. PMID:24217280. |
increased cerebrospinal fluid tau levels in logopenic variant of alzheimer's disease. |
2014-10-06 |
2023-08-12 |
Not clear |
Sergio Camero, María J Benítez, Alejandro Barrantes, José M Ayuso, Raquel Cuadros, Jesús Avila, Juan S Jiméne. Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone-DNA complex. Journal of Alzheimer's disease : JAD. vol 39. issue 3. 2014-10-06. PMID:24254705. |
tau protein has been proposed as a trigger of alzheimer's disease once it is hyperphosphorylated. |
2014-10-06 |
2023-08-12 |
Not clear |
Min-Kyoo Shin, Hong-Gi Kim, Seung-Hyun Baek, Woo-Ram Jung, Dong-Ik Park, Jong-Sung Park, Dong-Gyu Jo, Kil-Lyong Ki. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. Neurobiology of aging. vol 35. issue 5. 2014-10-06. PMID:24268884. |
alzheimer's disease (ad) is a neurodegenerative disease characterized by amyloid beta (aβ) deposits, hyperphosphorylated tau deposition, and cognitive dysfunction. |
2014-10-06 |
2023-08-12 |
mouse |
Filipa I Baptista, Ana G Henriques, Artur M S Silva, Jens Wiltfang, Odete A B da Cruz e Silv. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS chemical neuroscience. vol 5. issue 2. 2014-10-06. PMID:24328060. |
alzheimer's disease is characterized by pathological aggregation of protein tau and amyloid-β peptides, both of which are considered to be toxic to neurons. |
2014-10-06 |
2023-08-12 |
Not clear |
Filipa I Baptista, Ana G Henriques, Artur M S Silva, Jens Wiltfang, Odete A B da Cruz e Silv. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS chemical neuroscience. vol 5. issue 2. 2014-10-06. PMID:24328060. |
experimental evidence supports the hypothesis that certain flavonoids may protect against alzheimer's disease in part by interfering with the generation and assembly of amyloid-β peptides into neurotoxic oligomeric aggregates and also by reducing tau aggregation. |
2014-10-06 |
2023-08-12 |
Not clear |
b' Yash B Joshi, Phillip F Giannopoulos, Jin Chu, Domenico Pratic\\xc3\\xb. Modulation of lipopolysaccharide-induced memory insult, \\xce\\xb3-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase. Neurobiology of aging. vol 35. issue 5. 2014-10-06. PMID:24332986.' |
besides amyloid and tau pathology, a constant feature of alzheimer's disease (ad) is an intense inflammatory response, which is considered an active player in its pathogenesis. |
2014-10-06 |
2023-08-12 |
mouse |
Khalid Iqbal, Cheng-Xin Gong, Fei Li. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert opinion on therapeutic targets. vol 18. issue 3. 2014-10-06. PMID:24387228. |
microtubule-associated protein tau as a therapeutic target in alzheimer's disease. |
2014-10-06 |
2023-08-12 |
Not clear |
Ilie-Cosmin Stancu, Laurence Ris, Bruno Vasconcelos, Claudia Marinangeli, Léonie Goeminne, Vincent Laporte, Laetitia E Haylani, Julien Couturier, Olivier Schakman, Philippe Gailly, Nathalie Pierrot, Pascal Kienlen-Campard, Jean-Noël Octave, Ilse Dewachte. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 28. issue 6. 2014-10-06. PMID:24604080. |
tau alterations are now considered an executor of neuronal demise and cognitive dysfunction in alzheimer's disease (ad). |
2014-10-06 |
2023-08-12 |
mouse |
Masato Hasegawa, Sayuri Watanabe, Hiromi Kondo, Haruhiko Akiyama, David M A Mann, Yuko Saito, Shigeo Murayam. 3R and 4R tau isoforms in paired helical filaments in Alzheimer's disease. Acta neuropathologica. vol 127. issue 2. 2014-09-30. PMID:24212601. |
3r and 4r tau isoforms in paired helical filaments in alzheimer's disease. |
2014-09-30 |
2023-08-12 |
Not clear |
Manuela Polydoro, Volodymyr I Dzhala, Amy M Pooler, Samantha B Nicholls, A Patrick McKinney, Laura Sanchez, Rose Pitstick, George A Carlson, Kevin J Staley, Tara L Spires-Jones, Bradley T Hyma. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta neuropathologica. vol 127. issue 2. 2014-09-30. PMID:24271788. |
soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early alzheimer's disease model. |
2014-09-30 |
2023-08-12 |
mouse |
Julia Banzhaf-Strathmann, Eva Benito, Stephanie May, Thomas Arzberger, Sabina Tahirovic, Hans Kretzschmar, André Fischer, Dieter Edbaue. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. The EMBO journal. vol 33. issue 15. 2014-09-30. PMID:25001178. |
microrna-125b induces tau hyperphosphorylation and cognitive deficits in alzheimer's disease. |
2014-09-30 |
2023-08-13 |
mouse |
Jillian C Belrose, Raheleh Masoudi, Bernadeta Michalski, Margaret Fahnestoc. Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. Neurobiology of aging. vol 35. issue 4. 2014-09-29. PMID:24112788. |
aggregated amyloid-β has been shown to down-regulate specific bdnf transcripts in alzheimer's disease, but the role of tau pathology in neurotrophin dysregulation has not been investigated. |
2014-09-29 |
2023-08-12 |
human |
Jillian C Belrose, Raheleh Masoudi, Bernadeta Michalski, Margaret Fahnestoc. Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. Neurobiology of aging. vol 35. issue 4. 2014-09-29. PMID:24112788. |
these findings implicate tau pathology in neurotrophin dysregulation, which may represent a mechanism through which tau confers toxicity in alzheimer's disease and related non-alzheimer's dementias. |
2014-09-29 |
2023-08-12 |
human |
Timothy J Hohman, Mary Ellen I Koran, Tricia A Thornton-Well. Interactions between GSK3β and amyloid genes explain variance in amyloid burden. Neurobiology of aging. vol 35. issue 3. 2014-09-29. PMID:24112793. |
the driving theoretical framework of alzheimer's disease (ad) has been built around the amyloid-β (aβ) cascade in which amyloid pathology precedes and drives tau pathology. |
2014-09-29 |
2023-08-12 |
Not clear |
Matthew R Brier, Jewell B Thomas, Anne M Fagan, Jason Hassenstab, David M Holtzman, Tammie L Benzinger, John C Morris, Beau M Ance. Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of aging. vol 35. issue 4. 2014-09-29. PMID:24216223. |
alzheimer's disease (ad) has a long preclinical phase in which amyloid and tau cerebral pathology accumulate without producing cognitive symptoms. |
2014-09-29 |
2023-08-12 |
human |
Aaron Carman, Sarah Kishinevsky, John Koren, Wenjie Luo, Gabriela Chiosi. Regulatory chaperone complexes in neurodegenerative diseases: a perspective on therapeutic intervention. Current Alzheimer research. vol 11. issue 1. 2014-09-29. PMID:24251390. |
these species, called chaperone client proteins, include the pathogenic factors of numerous neurodegenerative disorders, including tau in alzheimer's disease, α-synuclein and lrrk2 in parkinson's disease, sod-1, tdp-43 and fus in amyotrophic lateral sclerosis, and polyq-expanded proteins such as huntingtin in huntington's disease. |
2014-09-29 |
2023-08-12 |
Not clear |